NEWS AND VIEWS FROM THE PHARMACEUTICAL FINE CHEMICAL AND CUSTOM MANUFACTURING SECTOR

Tuesday 5 February 2013

Lonza starts to restructure

Lonza will combine its custom manufacturing and bioscience business units into a pharma market segments group. The microbial control and life science ingredients businesses will be regrouped into a specialty ingredients market segments group. The company has also restructured its renamed Executive Committee. The committee will and will consist of five members: Richard Ridinger - CEO, Toralf Haag - CFO, Marc Funk - CLO, Stephan Kutzer - COO and Beat In-Albon - COO.
In-pharma Technologist

No comments: